|Original language||English (US)|
|Journal||Circulation: Heart Failure|
|State||Published - Aug 1 2022|
Bibliographical noteFunding Information:
Drs Prisco and Prins have a provisional patent for use of SC-144 in right ventricular dysfunction. Dr Prins served on an advisory board for Actelion and Edwards and receives grant funding from United Therapeutics.
Dr Prisco is funded by National Institutes of Health (NIH) F32 HL154533 and a University of Minnesota Clinical and Translational Science award (NIH UL1 TR002494). Dr Prins is funded by NIH K08 HL140100 and R01s HL162927 and HL158795 and American Lung Association Innovative Award IA-816386. The content is solely the responsibility of the authors and does not represent the official views of the NIH or any other funding sources.
PubMed: MeSH publication types
- Research Support, Non-U.S. Gov't
- Research Support, N.I.H., Extramural